JP2021502391A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502391A5
JP2021502391A5 JP2020526142A JP2020526142A JP2021502391A5 JP 2021502391 A5 JP2021502391 A5 JP 2021502391A5 JP 2020526142 A JP2020526142 A JP 2020526142A JP 2020526142 A JP2020526142 A JP 2020526142A JP 2021502391 A5 JP2021502391 A5 JP 2021502391A5
Authority
JP
Japan
Prior art keywords
composition
composition according
allergies
bacterial strains
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020526142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502391A (ja
JP7293220B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060187 external-priority patent/WO2019094837A1/en
Publication of JP2021502391A publication Critical patent/JP2021502391A/ja
Publication of JP2021502391A5 publication Critical patent/JP2021502391A5/ja
Priority to JP2023093879A priority Critical patent/JP2023121755A/ja
Application granted granted Critical
Publication of JP7293220B2 publication Critical patent/JP7293220B2/ja
Priority to JP2025105253A priority patent/JP2025170783A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020526142A 2017-11-09 2018-11-09 アレルギーの処置のための組成物および方法 Active JP7293220B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023093879A JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762583777P 2017-11-09 2017-11-09
US62/583,777 2017-11-09
US201862637355P 2018-03-01 2018-03-01
US62/637,355 2018-03-01
US201862721786P 2018-08-23 2018-08-23
US62/721,786 2018-08-23
PCT/US2018/060187 WO2019094837A1 (en) 2017-11-09 2018-11-09 Compositions and methods for the treatment of allergy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093879A Division JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021502391A JP2021502391A (ja) 2021-01-28
JP2021502391A5 true JP2021502391A5 (enExample) 2021-12-16
JP7293220B2 JP7293220B2 (ja) 2023-06-19

Family

ID=66438676

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526142A Active JP7293220B2 (ja) 2017-11-09 2018-11-09 アレルギーの処置のための組成物および方法
JP2023093879A Pending JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A Pending JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023093879A Pending JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A Pending JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Country Status (7)

Country Link
US (1) US20220054556A1 (enExample)
EP (1) EP3706767A4 (enExample)
JP (3) JP7293220B2 (enExample)
CN (1) CN111526882A (enExample)
AU (1) AU2018365071B2 (enExample)
CA (1) CA3081978A1 (enExample)
WO (1) WO2019094837A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410954A3 (en) 2017-12-11 2025-01-15 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US20220389369A1 (en) * 2019-09-16 2022-12-08 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
WO2022178292A1 (en) 2021-02-18 2022-08-25 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621083C (en) * 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
EP3569690B1 (en) * 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) * 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MX387331B (es) * 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.
CN115252650A (zh) * 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
WO2017160944A2 (en) * 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
PT3468573T (pt) * 2016-06-14 2023-10-16 Vedanta Biosciences Inc Tratamento de uma infeção por clostridium difficile
WO2018187272A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US10507221B2 (en) * 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
CN114502183A (zh) * 2019-08-09 2022-05-13 韦丹塔生物科学股份有限公司 用于阻抑病原生物体的组合物和方法

Similar Documents

Publication Publication Date Title
US11760970B2 (en) Lactobacillus plantarum and composition comprising the same
EP2522358B1 (en) Peptides against rotavirus infection
CN102292431B (zh) 一种植物乳杆菌及含该植物乳杆菌的组合物
Shigwedha Probiotical cell fragments (PCFs) as “novel nutraceutical ingredients”
CN113906129A (zh) 嗜黏蛋白阿克曼菌eb-amdk19菌株及其用途
Gao et al. Ability of Lactobacillus plantarum lipoteichoic acid to inhibit Vibrio anguillarum-induced inflammation and apoptosis in silvery pomfret (Pampus argenteus) intestinal epithelial cells
CN106413724B (zh) 与多糖聚合物粘合剂缀合的鼠李糖乳杆菌rht-3201及其用途
Hong et al. Different immune regulatory potential of Lactobacillus plantarum and Lactobacillus sakei isolated from kimchi
JP2023121755A5 (enExample)
JP2021502391A5 (enExample)
Ali et al. Heat-killed Limosilactobacillus reuteri PSC102 ameliorates impaired immunity in cyclophosphamide-induced immunosuppressed mice
Giri et al. Effects of intracellular products of Bacillus subtilis VSG1 and Lactobacillus plantarum VSG3 on cytokine responses in the head kidney macrophages of Labeo rohita
Lazarenko et al. Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties
JP6713751B2 (ja) 抗原に対する特異的な細胞傷害性t細胞(ctl)及び抗体産生を増強させる方法
Siddique et al. The Immunomodulatory Role
Soltani et al. Probiotic, paraprobiotic, and postbiotic as an alternative to antibiotic therapy for lactococcosis in aquaculture
TWI598103B (zh) 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌gmnl-296組合物及方法
KR101898138B1 (ko) 면역 조절 t 세포를 유도하는 락토코커스 락티스 bfe920 균주를 포함하는 수산양식 기능성 사료 첨가제
KR20180112257A (ko) 어류의 에드워드병 예방 또는 치료용 약학 조성물, 및 어류의 에드워드병 예방 및 치료 방법
JP2022025973A (ja) 紅藻類を含む免疫賦活剤
Rabetafika et al. Probiotics as Antibiotic Alternatives for Human and Animal Applications. Encyclopedia 2023, 3, 561–581
Wong et al. Potential biocontrol for bacterial and viral disease treatment in aquaculture: a minireview
Kamilya et al. Probiotics as Vaccine Adjuvants
Qi et al. Effect of oral administration of Lactobacillus acidophilus on the intestinal mucosal immune cells in young bactrian camels (Camelus bactrianus)
CN1269490C (zh) 抑制感染组合物及含有该组合物的饮食品